Submitted by Anonymous (not verified) on 3 August 2026 - 16:00
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 25, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 25, Status: Authorised